{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:22:17Z","timestamp":1780582937576,"version":"3.54.1"},"reference-count":67,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the General Program of the National Natural Science Foundation of China","award":["82172244"],"award-info":[{"award-number":["82172244"]}]},{"name":"the General Program of the National Natural Science Foundation of China","award":["2021YFC2302500"],"award-info":[{"award-number":["2021YFC2302500"]}]},{"name":"the National Key R and D Program of China","award":["82172244"],"award-info":[{"award-number":["82172244"]}]},{"name":"the National Key R and D Program of China","award":["2021YFC2302500"],"award-info":[{"award-number":["2021YFC2302500"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Human immunodeficiency virus (HIV)-infected individuals have an increased risk of various infections due to their impaired host immune system, resulting in higher morbidity and mortality rates. These patients severely suffered during the COVID-19 epidemic, the influenza epidemic and the spread of monkeypox. Reducing serious infections is one of the most important measures to improve HIV-infected individuals\u2019 quality and length of life. Based on the preparation processes and their antigenic properties, vaccines are divided into several types, including inactivated vaccines, attenuated live vaccines, recombinant protein vaccines, toxoid vaccines, polysaccharide vaccines, polysaccharide (protein) combined vaccines, nucleic acid vaccines, viral vector vaccines, etc. With the innovation of vaccine preparation technology in recent years and the acceleration of vaccine approval and market launch, more and more vaccine products suitable for HIV-infected individuals have become available. Because of their deficient immune systems, the type of vaccines and the schedule of vaccinations available to individuals living with HIV are sometimes different from those with healthy immune systems. This article reviewed the current status of vaccination in and shed light on the vaccination strategies for HIV-infected persons in terms of their safety and effectiveness.<\/jats:p>","DOI":"10.3390\/v17020171","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T04:59:10Z","timestamp":1737953950000},"page":"171","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Current Status in Terms of Vaccination for Individuals Infected with Human Immunodeficiency Virus"],"prefix":"10.3390","volume":"17","author":[{"given":"Nan","family":"Xu","sequence":"first","affiliation":[{"name":"Division of HIV\/AIDS and Sex-Transmitted Virus Vaccines, National Institute for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, Beijing 102629, China"},{"name":"Division of HIV\/AIDS and Sex-Transmitted Virus Vaccines, National Institute for Food and Drug Control (NIFDC), NHC Key Laboratory of Research on Quality and Biological Products, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Shen","sequence":"additional","affiliation":[{"name":"Division of HIV\/AIDS and Sex-Transmitted Virus Vaccines, National Institute for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, Beijing 102629, China"},{"name":"Division of HIV\/AIDS and Sex-Transmitted Virus Vaccines, National Institute for Food and Drug Control (NIFDC), NHC Key Laboratory of Research on Quality and Biological Products, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4246-8889","authenticated-orcid":false,"given":"Weijin","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of HIV\/AIDS and Sex-Transmitted Virus Vaccines, National Institute for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, Beijing 102629, China"},{"name":"Division of HIV\/AIDS and Sex-Transmitted Virus Vaccines, National Institute for Food and Drug Control (NIFDC), NHC Key Laboratory of Research on Quality and Biological Products, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-0427","authenticated-orcid":false,"given":"Jianhui","family":"Nie","sequence":"additional","affiliation":[{"name":"Division of HIV\/AIDS and Sex-Transmitted Virus Vaccines, National Institute for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, Beijing 102629, China"},{"name":"Division of HIV\/AIDS and Sex-Transmitted Virus Vaccines, National Institute for Food and Drug Control (NIFDC), NHC Key Laboratory of Research on Quality and Biological Products, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1080\/21645515.2016.1277844","article-title":"Hepatitis B virus vaccination in HIV-infected people: A review","volume":"13","author":"Catherine","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1086\/339044","article-title":"Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: Clinical, immunologic, and virologic responses","volume":"34","author":"Tasker","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00006454-200101000-00008","article-title":"Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy","volume":"20","author":"Dankner","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_4","unstructured":"(2021). Notice of the National Health Commission on the Issuance of the National Immunization Program Vaccine Child Immunization Procedures and Instructions (2021 Edition), China National Health CDC [2021] No. 10.2021."},{"key":"ref_5","unstructured":"(2020). Guidelines for the Use of Vaccines in Non-Immunization Programs (2020 Edition)."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1111\/hiv.12424","article-title":"British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015","volume":"17","author":"Geretti","year":"2016","journal-title":"HIV Med."},{"key":"ref_7","unstructured":"NIH (2025, January 15). Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV How to Cite the Adult and Adolescent Opportunistic Infection Guidelines: Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/."},{"key":"ref_8","unstructured":"World Health Organization (2021). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach, WHO."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.15585\/mmwr.mm7119a2","article-title":"Progress Toward Polio Eradication\u2014Worldwide, January 2020\u2013April 2022","volume":"71","author":"Rachlin","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_10","unstructured":"World Health Organization (2004). Global Polio Eradication Initiative, strategic plan 2004\u20132008. Wkly. Epidemiol. Rec., 79, 55\u201357."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0022-3476(85)80505-9","article-title":"Defective humoral immunity in pediatric acquired immune deficiency syndrome","volume":"107","author":"Bernstein","year":"1985","journal-title":"J. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00144802","article-title":"Antibody response to inactivated polio vaccine (E-IPV) in children born to HIV positive mothers","volume":"8","author":"Barbi","year":"1992","journal-title":"Eur. J. Epidemiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/21645515.2015.1076599","article-title":"Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine","volume":"12","author":"Seo","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1089\/apc.2014.0121","article-title":"Vaccination in HIV-infected adults","volume":"28","author":"Wallace","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"ref_15","first-page":"1","article-title":"Influenza vaccination in HIV-positive subjects: Latest evidence and future perspective","volume":"54","author":"Ceravolo","year":"2013","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1016\/j.vaccine.2023.05.055","article-title":"Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults","volume":"41","author":"Liu","year":"2023","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/cid\/ciq019","article-title":"Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: A prospective study comparing HIV-infected adults with HIV-uninfected adults","volume":"52","author":"Eberly","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/09564624231220424","article-title":"A meta-analysis of immunogenicity and safety of two versus single-doses of influenza A (H1N1) vaccine in person living with HIV","volume":"35","author":"Zhang","year":"2024","journal-title":"Int. J. STD AIDS"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJM199801293380503","article-title":"Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C","volume":"338","author":"Vento","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/605292","article-title":"Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America","volume":"49","author":"Aberg","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"i-KK4","DOI":"10.1097\/01.inf.0000437856.09540.11","article-title":"Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics","volume":"32","author":"Siberry","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/infdis\/171.Supplement_1.S44","article-title":"Clinical experience with an inactivated hepatitis A vaccine","volume":"171","author":"Clemens","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/01.aids.0000186815.99993.55","article-title":"Response to hepatitis A vaccine in HIV patients in the HAART era","volume":"19","author":"Rimland","year":"2005","journal-title":"AIDS"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2893.2005.00658.x","article-title":"Response to hepatitis A vaccine in HIV-positive patients","volume":"13","author":"Weissman","year":"2006","journal-title":"J. Viral Hepat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.vaccine.2005.07.102","article-title":"Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: A hierarchical bayesian meta-analysis","volume":"24","author":"Shire","year":"2006","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/374562","article-title":"Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: A double-blind, randomized, placebo-controlled trial","volume":"187","author":"Kemper","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"De Vito, A., Colpani, A., Trunfio, M., Fiore, V., Moi, G., Fois, M., Leoni, N., Ruiu, S., Babudieri, S., and Calcagno, A. (2023). Living with HIV and Getting Vaccinated: A Narrative Review. Vaccines, 11.","DOI":"10.3390\/vaccines11050896"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12981-021-00416-1","article-title":"Adverse events of inactivated COVID-19 vaccine in HIV-infected adults","volume":"18","author":"Wu","year":"2021","journal-title":"AIDS Res. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/08959420.2023.2195348","article-title":"\u201cI\u2019m Getting Life from the Treatment\u201d: Perceptions of Life and Death Among Middle-Aged and Older Medication-Adherent Persons Living with HIV in Rural South Africa","volume":"36","author":"David","year":"2023","journal-title":"J. Aging Soc. Policy"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wu, S., Zou, S., Ming, F., Wu, M., Guo, W., Xing, Z., Zhang, Z., Liu, J., Tang, W., and Liang, K. (2023). Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-07982-x"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zou, S., Guo, W., Wu, S., Ming, F., Tan, Y., Wu, M., Tang, W., and Liang, K. (2022). Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.988304"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/519169","article-title":"Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: An observational study","volume":"196","author":"Moss","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1093\/infdis\/jiaa573","article-title":"Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster","volume":"224","author":"Gershon","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1067\/mpd.2001.115972","article-title":"Immunization of HIV-infected children with varicella vaccine","volume":"139","author":"Levin","year":"2001","journal-title":"J. Pediatr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0891-5520(05)70314-7","article-title":"The varicella vaccine. Clinical trials in immunocompromised individuals","volume":"10","author":"Gershon","year":"1996","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s42770-020-00417-8","article-title":"Detection and evaluation of rotavirus surveillance methods as viral indicator in the aquatic environments","volume":"52","author":"Atabakhsh","year":"2021","journal-title":"Braz. J. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/j.vaccine.2011.09.026","article-title":"Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants","volume":"30","author":"Laserson","year":"2012","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1093\/cid\/civ1204","article-title":"Temporal Association of Rotavirus Vaccine Introduction and Reduction in All-Cause Childhood Diarrheal Hospitalizations in South Africa","volume":"62","author":"Groome","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAD.0000000000001258","article-title":"Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa","volume":"31","author":"Levin","year":"2017","journal-title":"AIDS"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","article-title":"High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load","volume":"157","author":"Tseng","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Njom Nlend, A.E., Nguwoh, P.S., Ngounouh, C.T., Tchidjou, H.K., Pieme, C.A., Otele, J.M., Penlap, V., Colizzi, V., Moyou, R.S., and Fokam, J. (2016). HIV-Infected or -Exposed Children Exhibit Lower Immunogenicity to Hepatitis B Vaccine in Yaounde, Cameroon: An Appeal for Revised Policies in Tropical Settings?. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161714"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2013.10.029","article-title":"Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants","volume":"60","author":"Chasela","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/QAD.0000000000001765","article-title":"HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer","volume":"32","author":"Liu","year":"2018","journal-title":"AIDS"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/QAD.0b013e3283023f78","article-title":"Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy","volume":"22","author":"Piketty","year":"2008","journal-title":"AIDS"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/aje\/kwt153","article-title":"Risk factors for anal cancer in persons infected with HIV: A nested case-control study in the Swiss HIV Cohort Study","volume":"178","author":"Bertisch","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Grace, D., Gaspar, M., Paquette, R., Rosenes, R., Burchell, A.N., Grennan, T., and Salit, I.E. (2018). HIV-positive gay men\u2019s knowledge and perceptions of Human Papillomavirus (HPV) and HPV vaccination: A qualitative study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207953"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1016\/j.vaccine.2014.08.011","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults","volume":"32","author":"Giacomet","year":"2014","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Rungmaitree, S., Thepthai, C., Toh, Z.Q., Musiwiraphat, N., Maleesatharn, A., Rermruay, R., Sungkate, S., Phongsamart, W., Lapphra, K., and Wittawatmongkol, O. (2022). Immunogenicity of a Two-Dose Human Papillomavirus Vaccine Schedule in HIV-Infected Adolescents with Immune Reconstitution. Vaccines, 10.","DOI":"10.3390\/vaccines10010118"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coviro.2017.03.012","article-title":"Vaccine development for respiratory syncytial virus","volume":"23","author":"Graham","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons","volume":"78","author":"Ison","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01974608","article-title":"Bordetella pertussis as a cause of chronic respiratory infection in an AIDS patient","volume":"13","author":"Colebunders","year":"1994","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/clinids\/21.5.1197","article-title":"Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus","volume":"21","author":"Kroon","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.4161\/hv.32247","article-title":"Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy","volume":"10","author":"Lee","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Romaru, J., Bahuaud, M., Lejeune, G., Hentzien, M., Berger, J.L., Robbins, A., Lebrun, D., N\u2019Guyen, Y., Bani-Sadr, F., and Batteux, F. (2021). Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV\u2014Immunological Response and Protection. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.791147"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(09)61203-4","article-title":"Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: Global estimates","volume":"374","author":"Watt","year":"2009","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.vaccine.2020.02.026","article-title":"Effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines","volume":"38","author":"Madhi","year":"2020","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1038\/s41467-022-32263-7","article-title":"Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV","volume":"13","author":"Vergori","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/cid\/ciab648","article-title":"The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)","volume":"74","author":"Woldemeskel","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100287","DOI":"10.1016\/j.lanepe.2021.100287","article-title":"Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: A prospective single-centre cohort study","volume":"13","author":"Lombardi","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1742457","DOI":"10.1080\/19420862.2020.1742457","article-title":"Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors","volume":"12","author":"Fan","year":"2020","journal-title":"MAbs"},{"key":"ref_62","unstructured":"(2024, November 10). World Health Organization. Multi-Country Monkeypox Outbreak in Non-Endemic Countries. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON385."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"764","DOI":"10.15585\/mmwr.mm7123e1","article-title":"Monkeypox Outbreak\u2014Nine States, May 2022","volume":"71","author":"Minhaj","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa2207323","article-title":"Monkeypox Virus Infection in Humans across 16 Countries\u2014April\u2013June 2022","volume":"387","author":"Thornhill","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2666-5247(23)00410-X","article-title":"SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: A phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial","volume":"5","author":"Scott","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/tmi.13979","article-title":"Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials","volume":"29","author":"Rodrigue","year":"2024","journal-title":"Trop. Med. Int. Health"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(15)60310-5","article-title":"Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"Zeng","year":"2015","journal-title":"Lancet"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:16Z","timestamp":1759919776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["v17020171"],"URL":"https:\/\/doi.org\/10.3390\/v17020171","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]}}}